Sector: Health Care
Director information for KODIAK SCIENCES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bassil I. Dahiyat, Ph.D. | Director; Board Member | 55 | ["President and Chief Executive Officer of Xencor, Inc. since February 2005","Co-founded Xencor in 1997","Served as Chief Executive Officer from 1997 to 2003","Served as Chief Scientific Officer from 2003 to 2005","Recognized as a technology pioneer by the World Economic Forum in 2005","Named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review","Received awards from the American Chemical Society, the Controlled Release Society, and the California Institute of Technology","Holds a Ph.D. in Chemistry from the California Institute of Technology","B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University"] | ["Audit"] | 2026 |
| Charles A. Bancroft | Director; Board Member | 66 | ["Leadership roles in commercial, strategy and finance at Bristol-Myers Squibb","Chief Financial Officer of Bristol-Myers Squibb from January 2010 to November 2019","Independent director of GSK","Independent director of Biovector, Inc.","Member of the board of directors of Colgate-Palmolive Company from January 2017 to March 2020","Bachelor's degree from Drexel University","M.B.A. from Temple University"] | ["Audit","Compensation","Nominating and Governance","Nominating and Corporate Governance"] | 2026 |
| Felix J. Baker, Ph.D. | Director; Board Member | 57 | ["Managing Member of Baker Bros. Advisors LP","Ph.D. in Immunology from Stanford University","Experience as a board member and investor in biotechnology companies"] | ["Compensation","Nominating and Governance","Nominating and Corporate Governance"] | 2026 |
| Richard S. Levy, M.D. | Director; Board Member | 68 | ["senior advisor of Baker Bros. Advisors LP","Executive Vice President and Chief Drug Development Officer of Incyte Corporation","Senior Vice President of Drug Development at Incyte","Vice President, Biologic Therapies at Celgene Corporation","various executive positions with DuPont Pharmaceuticals","Assistant Professor of Medicine at UCLA School of Medicine"] | ["Nominating and Governance","Nominating and Corporate Governance"] | 2026 |
| Robert A. Profusek, J.D. | Director; Board Member | 76 | ["Partner of the Jones Day law firm","Global chair of the firm’s mergers and acquisitions practice","Expertise in mergers, acquisitions, takeovers, restructurings and corporate governance matters","Lead Independent Director of CTS Corporation","Director of three other publicly traded companies","B.A. from Cornell University","J.D. from New York University"] | ["Compensation","Nominating and Governance","Nominating and Corporate Governance"] | 2026 |
| Taiyin Yang, Ph.D. | Director; Board Member | 72 | ["Former Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc.","Directed operations of chemical and biologics process development, device and formulation development, and site operations.","Developed the world’s first HIV single tablet regimen and advanced over 25 compounds to market.","Bachelor’s degree in Chemistry from National Taiwan University.","Ph.D. in Organic Chemistry from the University of Southern California.","Fellow of the American Institute for Medical and Biological Engineering (2021).","Member of the National Academy of Engineering (2022)."] | ["Audit"] | 2026 |
| Victor Perlroth, M.D. | Chairman and Chief Executive Officer | 53 | ["co-founder of Kodiak Sciences Inc.","Chairman and Chief Executive Officer since 2009","experienced in biopharmaceuticals drug discovery and development","previously chief operating officer at Guzik Technical Enterprises","worked at Nortel Networks"] | [] | 2026 |
